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Introduction {#ccr3436-sec-0001}
============

Neurolymphomatosis, the direct infiltration of lymphoma cells into the peripheral or cranial nerves, occurs very rarely in lymphoma patients [1](#ccr3436-bib-0001){ref-type="ref"}. It manifests chiefly in aggressive B‐cell or T‐cell lymphomas and is not normally diagnosed in patients with low‐grade lymphomas such as follicular lymphoma [2](#ccr3436-bib-0002){ref-type="ref"}. There is no standard treatment for neurolymphomatosis because of the scarcity of clinical studies. We report the successful treatment of neurolymphomatosis caused by follicular lymphoma with bendamustine.

Case history {#ccr3436-sec-0002}
============

A 47‐year‐old woman with a history of follicular lymphoma presented with severe pain in her left leg. She had been diagnosed with follicular lymphoma Grade I at age 30 years, and she had been assigned a low‐risk classification according to the follicular lymphoma international prognostic index(FLIPI) score. Complete remission was achieved after eight courses of the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone). After the first complete remission, the patient experienced multiple relapses, and she was treated with a combination of chemotherapy and focal radiotherapy (Table [1](#ccr3436-tbl-0001){ref-type="table-wrap"}), achieving complete remission each time.

###### 

Treatments provided from the onset of neurolymphomatosis

                     Age   Radiation                  Regimen                                           Agent                                                           
  ------------------ ----- -------------------------- ------------------------------------------------- -------------- ------------------ -------------- -------------- ---------------
  Primary lymphoma   30                               CHOP                                              Doxorubicin    Cyclophosphamide   Vincristine    Prednisolone   
  1st relapse        32    40 Gy on cervical region   MECP                                              Mitoxantrone   Etoposide          Carboplatine   Prednisolone   
  2nd relapse        40                               R+mitoxantrone                                    Rituximab      Mitoxantrone                                     
  3rd relapse        43    36 Gy on left femur        Rituxiamab monotherapy                            Rituximab                                                       
  4th relapse        44                                                                                                                                                 
  5th relapse        45                               R‐CHASE                                           Rituximab      Cyclophosphamide   Etoposide      Cytarabine     Dexamethasone
                                                      R‐MEAM and autologous stem cell transplantation   Rituximab      Ranimustine        Etoposide      Cytarabine     Melphalan
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On admission, the patient had difficulty walking because of the pain intensity. However, she did not report sensory loss in either leg or the presence of symptoms of bladder and bowel disturbances. Physical examination did not reveal peripheral lymphadenopathy or hepatosplenomegaly. Findings of neurologic examination of the cranial nerves were unremarkable. Upper and lower limb examination did not show motor dysfunction or sensory loss, and tendon reflexes were normal. Gadolinium‐enhanced magnetic resonance imaging (MRI) revealed enlargement and strong postgadolinium enhancement of the left sacral nerve root, findings consistent with neurolymphomatosis (Fig. [1](#ccr3436-fig-0001){ref-type="fig"}A). Positron emission tomography did not show uptake around the sacral nerve root or signs of lymphoma recurrence at other sites. Cytological examination and flow cytometric analysis of cerebrospinal fluid did not show any lymphoma infiltration. Because of the difficulty in performing a biopsy of the nerve, we diagnosed the patient with neurolymphomatosis clinically, and initiated a BR regimen (90 mg/m^2^ bendamustine on days 1 and 2 with 375 mg/m^2^ rituximab on day 1). The pain began to resolve 4 days later and disappeared completely by 2 weeks. MRI performed 3 weeks after chemotherapy revealed shrinkage of the lesion. The patient received six courses of BR, after which MRI showed no sign of the lesion (Fig. [1](#ccr3436-fig-0001){ref-type="fig"}B). No recurrence was observed 14 months postchemotherapy.

![Coronal images from gadolinium‐enhanced magnetic resonance imaging at initial diagnosis of neurolymphomatosis (Panel A), and after treatment with bendamustine (Panel B). Enlargement and strong postgadolinium enhancement of the left sacral nerve that was observed at diagnosis (Panel A, arrow) disappeared after six courses of treatment with bendamustine and rituximab (Panel B, arrow).](CCR3-4-023-g001){#ccr3436-fig-0001}

Discussion {#ccr3436-sec-0003}
==========

Systemic chemotherapy, including methotrexate, and intrathecal chemotherapy as well as radiotherapy have traditionally been used for treating neurolymphomatosis. However, their effectiveness is unclear because there are no standardized criteria to measure treatment response [1](#ccr3436-bib-0001){ref-type="ref"}. Methotrexate, which penetrates the blood--brain and blood--nerve barriers, can cause renal impairment and mucositis, especially when administered in a high dose. Bendamustine is effective for treating relapsed or refractory indolent lymphoma [3](#ccr3436-bib-0003){ref-type="ref"}. However, there are no reports of bendamustine penetrating the human blood--brain or blood--nerve barriers, although another investigation showed that bendamustine does cross the murine blood--brain barrier [4](#ccr3436-bib-0004){ref-type="ref"}. Retrospective studies also showed the efficacy of bendamustine for recurrent primary central nervous system lymphoma [5](#ccr3436-bib-0005){ref-type="ref"}, [6](#ccr3436-bib-0006){ref-type="ref"} and brain metastasis of breast cancer [7](#ccr3436-bib-0007){ref-type="ref"}. To the best of our knowledge, this is the first report indicating that bendamustine can cross the human blood--nerve barrier, and evidence suggests that bendamustine may be effective not only for CNS lymphoma, but also for neurolymphomatosis caused by follicular lymphoma.
